
Telomir Pharmaceuticals, Inc. — Investor Relations & Filings
Telomir Pharmaceuticals, Inc. is a pre-clinical stage pharmaceutical company focused on the development of Telomir-1, its lead product candidate. Telomir-1 is an investigational oral small molecule designed to address the cellular drivers of aging and chronic disease. Its proposed mechanism of action involves regulating intracellular metals, such as iron and copper, to interrupt enzyme function. The therapy aims to extend and protect telomeres, reset abnormal DNA methylation patterns, reduce oxidative stress, and restore mitochondrial function. By targeting these fundamental processes, the company seeks to develop treatments for age-related conditions and specific disorders like Wilson's Disease.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K | 2026-05-20 | English | |
| 10-Q | 2026-05-14 | English | |
| 8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer) | 2026-04-24 | English | |
| 8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer) | 2026-03-31 | English | |
| 8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer) | 2026-03-31 | English | |
| 8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer) | 2026-03-27 | English |
Browse filings by year
4 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
13 filings
| |||||
| 46642344 | 8-K | 2026-05-20 | English | ||
| 46209544 | 10-Q | 2026-05-14 | English | ||
| 36131700 | 8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer) | 2026-04-24 | English | ||
| 33116048 | 8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer) | 2026-03-31 | English | ||
| 33112612 | 8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer) | 2026-03-31 | English | ||
| 33066053 | 8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer) | 2026-03-27 | English | ||
| 32968038 | 10-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer) | 2026-03-17 | English | ||
| 32267969 | 8-K Filing | 2026-02-17 | English | ||
| 32267919 | SCHEDULE 13G/A Filing | 2026-02-12 | English | ||
| 32267961 | 8-K Filing | 2026-02-05 | English | ||
| 13650689 | PRER14A | 2026-01-23 | English | ||
| 13650688 | 8-K | 2026-01-10 | English | ||
| 13650690 | 8-K | 2026-01-05 | English | ||
|
2025
2 filings
| |||||
| 13650691 | 8-K | 2025-12-20 | English | ||
| 13650692 | 8-K | 2025-12-17 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Beijing Sun-Novo Pharmaceutical Research Co.,Ltd.
Integrated CRO providing full-spectrum R&D from drug discov…
|
688621 | CN | Professional, scientific and te… |
|
BenevolentAI
Applies artificial intelligence to accelerate drug discover…
|
BAI | LU | Professional, scientific and te… |
|
Berry Genomics Co.,Ltd
Provides clinical genomics and genetic testing for prenatal…
|
000710 | CN | Professional, scientific and te… |
|
BetterLife Pharma
Developing non-hallucinogenic neuroplastogens for severe ne…
|
BETR | CA | Professional, scientific and te… |
|
BGI Genomics Co., Ltd.
Provides integrated solutions for precision medicine via ge…
|
300676 | CN | Professional, scientific and te… |
|
bioAffinity Technologies, Inc.
Develops noninvasive diagnostics and targeted therapeutics …
|
BIAF | US | Professional, scientific and te… |
|
BioArctic
Biopharmaceutical firm developing antibody therapies for ne…
|
BIOA | SE | Professional, scientific and te… |
|
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
Develops antibody therapeutics using proprietary RenMice ge…
|
688796 | CN | Professional, scientific and te… |
|
BIO-GENE TECHNOLOGY LTD
Develops novel insecticides from natural chemistry to comba…
|
BGT | AU | Professional, scientific and te… |
|
BioInfra Co.,Ltd.
Develops multi-biomarker blood tests for early cancer scree…
|
199730 | KR | Professional, scientific and te… |
Telomir Pharmaceuticals, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34700/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34700 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34700 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34700 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34700}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Telomir Pharmaceuticals, Inc. (id: 34700)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.